E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Advanced solid malignancies |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 15.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10048683 |
E.1.2 | Term | Advanced cancer |
E.1.2 | System Organ Class | 100000004864 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The main objective of this study is to determine whether tumor concentrations of kinase inhibitors at pharmacological active doses can be predicted from PET studies using tracer amounts (microdosing) of corresponding radiolabeled kinase inhibitors. This objective includes the development and validation of pharmacokinetic models for radiolabeled kinase inhibitors as well as validation of the microdosing concept for kinase inhibitors. |
|
E.2.2 | Secondary objectives of the trial |
The secondary objectives include exploration whether kinase inhibitor kinetics depend on perfusion (as measured by [15O]water PET) or size (as measured by diagnostic CT/MRI) of tumor lesions and to investigate (in)activation of key pathways targeted by the specific kinase inhibitor. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Patients must have a histologically confirmed diagnosis of an advanced or metastatic solid malignancy.
• Patients must have confirmed radiological or clinical progressive disease.
• Patients must have at least one measurable tumor lesion outside the liver.
• Indication for standard use of palliative systemic treatment, with preference for standard treatment of sorafenib or erlotinib.
• Age ≥ 18 years.
• ECOG Performance Status ≥ 2.
• Life expectancy of at least 12 weeks.
• Patients should be able to swallow oral medication.
• Adequate bone marrow, liver and renal function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:
o Hemoglobin > 6.0 mmol/L
o Absolute neutrophil count (ANC) >1,5 x 10*9/L
o Platelet count 100 x 10*9/L
o Total bilirubin < 2 times the upper limit of normal (ULN)
o ALT and AST < 2.5 x ULN; < 5x ULN in case of liver metastases, except for patients with hepatocellular carcinoma, than Child Pugh classification A-B.
o Alkaline phosphatase < 4 x ULN; < 5x ULN in case of liver metastases, except for patients with hepatocellular carcinoma, than Child Pugh classification A-B.
o Serum creatinine eGFR 50 mL/min.
o PT-INR/PTT < 1.5 x ULN, unless coumarin derivatives are used.
o Activated partial thromboplastin time < 1.25 x ULN (therapeutic anticoagulation therapy is allowed, if this treatment can be interrupted for a biopsy as judged by the treating physician).
|
|
E.4 | Principal exclusion criteria |
• Concurrent treatment with other anticancer agents or experimental drugs.
• History of cardiac disease:
o Congestive heart failure >NYHA class 2.
o Active Coronary Artery Disease (defined as myocardial infarction within 6 months prior to screening).
• Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted).
• Uncontrolled hypertension. Blood pressure must be ≤160/95 mmHg at the time of screening on a stable antihypertensive regimen. Blood pressure must be stable on at least 2 separate measurements.
• Uncontrolled infections (> grade 2 NCI-CTC version 4.0).
• Subjects with serious non-healing wound, ulcer, or bone fracture.
• Patients with thromboembolic events within 3 months prior to study inclusion.
• Significant skin condition interfering with treatment
• Patients undergoing renal dialysis.
• Pregnant or breast-feeding subjects. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must agree to use adequate barrier birth control measures (e.g., cervical cap, condom, or diaphragm) during the course of the trial. Oral birth control methods alone will not be considered adequate on this study, because of the potential pharmacokinetic interaction between study drug and oral contraceptives. Concomitant use of oral and barrier contraceptives is advised. Contraception is necessary for at least 6 months after receiving the study kinase inhibitor.
• Concomitant use of dexamethasone, anti-convulsants and anti-arrhythmic drugs other than digoxin or beta blockers.
• Major surgery within 28 days prior to start of treatment.
• Medical, psychological or social conditions that may interfere with the subject’s participation in the study or evaluation of the study results.
• Any condition that is unstable or could jeopardize the safety of the subject and their compliance in the study.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
- Detection of [11C]sorafenib or [11C]erlotinib in tumor lesions before and during treatment with sorafenib and erlotinib, respectively.
- Biodistribution of [11C]sorafenib or [11C]erlotinib before and during treatment with sorafenib and erlotinib, respectively.
- Pharmacokinetics of [11C]sorafenib or [11C]erlotinib before and during treatment with sorafenib and erlotinib, respectively.
- Tumorconcentrations of sorafenib or erlotinb after two weeks of treatment with sorafenib or erlotinib, respectively. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Before start of treatment with sorafenib or erlotinib patients will be injected with [11C]sorafenib or [11C]erlotinib, resepctively. Immediately after injection a dynamic PET scan (microdosing) will be performed together with continuous arterial sampling.
After two weeks of treatment with sorafenib or erlotinib patients will be injected a second time with [11C]sorafenib or [11C]erlotinib, resepctively. Immediately after injection a dynamic PET scan (therapeutic) will be performed together with continuous arterial sampling.
Within two hours after the therapeutic scan a tumor biopsy will be performed.
|
|
E.5.2 | Secondary end point(s) |
-phosphoproteomic analysis and (in)activation of key pathways invloved in sorafenib or erlotinib signaliing, resepectively.
- measurement of perfusion of tumor lesions using [15O] water PET scan
- size measurements of tumor lesions |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Immediately before the injection with [11C]sorafenib or [11C]erlotinib for the microdosing and the therapeutic PET scan, patients will be injected with [15O] water to perform a [15O]water PET scan.
Within two hours after the microdosing scan (optional) and therapeutic scan a tumor biopsy will be taken.
Tumor size will be measured on the diagnostic CT and/or MRI performed during screening. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |